BioCentury | May 19, 2020
Emerging Company Profile

Helmed by OrbiMed’s Wang, Inmagene debuts with Phase II autoimmune program

Inmagene emerged from stealth with a clinical psoriasis program from Swedish biotech Affibody. Inmagene emerged from stealth last week with plans to expand the biologics markets in China, starting with a Phase II psoriasis program...
BioCentury | Apr 24, 2020
Product Development

Upbeat Lilly earnings come with positive psoriasis results, delays for two autoimmune programs

Lilly announced positive Phase III data for autoimmune disease candidate mirikizumab and attributed a bump in revenue, adjusted guidance and trial delays to the COVID-19 pandemic. As part of its 1Q20 earnings, Eli Lilly and...
BioCentury | Mar 27, 2020
Regulation

CHMP decisions set stage for approval of Novartis’ SMA gene therapy, Celgene’s Zeposia for MS, Sanofi’s comeback cancer drug

EMA’s CHMP backed conditional approval of an MAA for Zolgensma to treat spinal muscular atrophy in its March set of recommendations, which were made via a virtual meeting because of the COVID-19 outbreak. The agency...
BC Extra | Jan 29, 2020
Company News

Launches fuel Novartis’ growth as CEO reiterates China commitment

With over 90% commercial payer coverage for SMA gene therapy Zolgensma and increased uptake for heart failure drug Entresto, Novartis posted nearly double-digit sales growth in 2019 as the pharma looks to additional new drugs...
BioCentury | Nov 7, 2019
Product Development

AZ replants R&D roots in China, goes all-in on innovation

In a big week for MNCs in China, AstraZeneca defined the latest move in its China strategy with an ‘all-in’ approach to innovation that goes full throttle by fostering R&D, AI and company formation. As...
BC Extra | Oct 24, 2019
Financial News

Lilly shares slide amid Trulicity, Taltz pricing concerns

Shares of Eli Lilly slid Wednesday after the company reported weaker-than-expected 3Q19 sales for drugs affected by high rebates and discounts. Eli Lilly and Co. (NYSE:LLY) lost $2.4 billion in market cap, closing the day...
BC Extra | Sep 13, 2019
Clinical News

Sept. 13 Clinical Quick Takes: Amgen, Atara, MS biomarkers and switching in psoriasis

Clinical holds on two Amgen trials for cardiac safety signal   Amgen (NASDAQ:AMGN) said FDA placed a clinical hold on a Phase I trial of MCL1 inhibitor AMG 397 “to evaluate a safety signal for...
BC Extra | Aug 13, 2019
Clinical News

Taltz tops Tremfya in psoriasis but data may not change prescribing habits

Eli Lilly said Taltz was superior to J&J's Tremfya in treating psoriasis at 12 weeks in the Phase IV IXORA-R trial, but the data may not move the needle on physicians’ prescribing habits. The data...
BC Extra | Jul 19, 2019
Company News

July 19 Company Quick Takes: First biosimilars of Avastin, Herceptin launched; plus Gilenya, Celltrion-Nan Fung and Celgene

Amgen, Allergan launch pair of biosimilars  Amgen Inc. (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) launched Mvasi bevacizumab-awwb and Kanjinti trastuzumab-anns in the U.S.; they are the first biosimilars of Avastin bevacizumab and Herceptin trastuzumab available in...
BC Extra | Jul 19, 2019
Company News

Payers, patients coming on board for Novartis’ Zolgensma

Novartis reported steady uptake for newly launched gene therapy Zolgensma, with about 40% of lives reimbursed via formal coverage policies and 17 payers signing up for the pharma’s novel pricing arrangement. But payers are resisting...
Items per page:
1 - 10 of 133